All In MedTech

Device Trial Radar · NCT03603600

Evaluate the Safety and Effectiveness of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens

A Prospective, Multicenter, Randomized, Active-Controlled Clinical Study to Evaluate the Safety and Effectiveness of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens in Subjects Undergoing Cataract Extraction

Last checked: Nov 19, 2026Latest source record: Dec 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 501 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

501

Actual

Start

May 31, 2018

Primary completion

May 4, 2023

Study completion May 4, 2023

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedNot on our public-company list
Sponsor type
Industry
First posted
Jul 27, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of the study is to evaluate the safety and effectiveness of the enVista trifocal intraocular lens when implanted in the capsular bag.

Conditions

  • Cataract

Interventions

  • enVista MX60EDevice

    enVista MX60E monofocal IOL

  • enVista MX60EFDevice

    enVista MX60EF (trifocal) multifocal IOL (MIOL)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Photopic Monocular Best-corrected Distance Visual Acuity (BCDVA)Time frame: Day 120 to Day 180 after second eye implantation, up to 210 days from first eye implantation at Baseline.
  2. Photopic Monocular Distance-corrected Near Visual Acuity (DCNVA)Time frame: Day 120 to Day 180 after second eye implantation, up to 210 days from first eye implantation at Baseline.
  3. Photopic Monocular Distance-corrected Intermediate Visual Acuity (DCIVA)Time frame: Day 120 to Day 180 after second eye implantation, up to 210 days from first eye implantation at Baseline.

3 more outcomes with a free account

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Bausch Site 108

    Fayetteville, Arkansas

  • Bausch Site 113

    Garden Grove, California

  • Bausch Site 120

    Northridge, California

20 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.